HY012

HY012 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by Juventas Cell Therapy for the treatment of Non-Hodgkin Lymphoma (NHL). Currently in the preclinical stage, HY012 is part of Juventas's expanding portfolio of cell-based immunotherapies. The therapy involves engineering a patient's T-cells to express a chimeric antigen receptor that recognizes and binds to specific antigens on the surface of lymphoma cells, though the exact target for HY012 has not been publicly specified in detail. Juventas Cell Therapy, a biotechnology company based in China, is leveraging its proprietary cell therapy platform to advance HY012 alongside its lead candidate, inaticabtagene autoleucel (CNCT19).